ANDOVER, Mass., Aug. 28, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference at the Sheraton New York. The fireside chat will take place on Monday, September 11, 2023, at 8:40 a.m. Eastern Time.
Event: Morgan Stanley 21st Annual Global Healthcare Conference
Date: Monday, September 11, 2023
Time: 8:40 a.m. ET
A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
332-895-3222
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$83.31 |
| Daily Change: | -5.19 -5.86 |
| Daily Volume: | 3,461,499 |
| Market Cap: | US$2.780B |
October 28, 2024 April 30, 2024 February 28, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
